NasdaqCM - Delayed Quote USD

SAB Biotherapeutics, Inc. (SABSW)

0.0241
-0.0088
(-26.75%)
At close: 4:00:00 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Samuel J. Reich CEO & Executive Chairman 782.1k -- 1975
Dr. Eddie Joe Sullivan Ph.D. Co-Founder, President & Director 744.38k -- 1967
Ms. Christine E. Hamilton M.B.A. Co-Founder & Independent Director 32k -- 1956
Ms. Lucy To Executive VP & CFO 165.13k -- 1986
Dr. Christoph Bausch M.B.A., Ph.D. Executive VP & COO 574.59k -- 1971
Dr. Alexandra Kropotova M.B.A., M.D. Executive VP & Chief Medical Officer 790.15k -- 1973
Dr. Edward D. Hamilton D.V.M. Co-Founder & Board Observer -- -- --
Dr. Carlos N. Carillo Ph.D. Senior Vice President of Regulatory Affairs -- -- --

SAB Biotherapeutics, Inc.

777 W 41st St.
Miami Beach, FL 33140
United States
605 679 6980 https://www.sabbiotherapeutics.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
63

Description

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

Corporate Governance

SAB Biotherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events